A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Clinical trial NCT02707666 · TERMINATED
Trial details
- NCT number
- NCT02707666
- Sponsor
- University of Chicago
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-25
- Primary completion
- 2023-04-24
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.